HER2 Low and Ultralow Designations Open Door to Expansion of ADCs in Breast Cancer

(MedPage Today) -- The HER2-low and HER2-ultralow breast cancer subtype designations have led to a changed landscape in HER2-directed therapies, as well as a desire for more sensitive assays that may better quantify HER2 expression.
The HER2-low...